Our perspectives
in one place
Topic
Selected filters
ClearNews
See allWHA78 individual statement on antimicrobial resistance (AMR)
On 27 May 2025, IFPMA delievered a statement at the 78th session of the World Health Assembly on antimicrobial resistance.
Read moreWHA78 Fight the Fakes Alliance statement on substandard and falsified medical products
On 26 May 2025, the World Heart Federation delivered a statement on substandard and falsified medicines at the 78th session of the World Health Assembly. The World Heart Federation, supported by the Fight the Fakes Alliance, welcomes the independent evaluation of the Member State Mechanism on Substandard and Falsified Medical Products. Globally, countries waste an...
Read moreWHA78 AMATA statement on substandard and falsified medical products
On 26 May 2025, the International Alliance of Patients' Organizations, on behalf of the African Medicines Agency Treaty Alliance (AMATA), delivered a statement on substandard and falsified medical products at the 78th session of the World Health Assembly. As a member of AMATA, IFPMA supported this statement.
Read moreIFPMA welcomes the adoption of the WHA78 Resolution on rare diseases
On 24 May 2025, a resolution on rare diseases was adopted at the 78th session of the World Health Assembly. IFPMA issued a statement in support of the resolution. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), together with its member companies and associations, welcomes the adoption of the World Health Assembly (WHA) Resolution...
Read moreWHA78 constituency statement on universal health coverage (UHC) and primary healthcare (PHC)
On 24 May 2025 at the 78th session of the World Health Assembly, the International Council of Nurses (ICN) delivered a statement on behalf of the World Health Professions Alliance (WHPA) on UHC and PHC.
Read moreWHA78 individual statement on non-communicable diseases
On 23 May 2025, IFPMA delivered a statement at the 78th session of the World Health Assembly on non-communicable diseases. IFPMA welcomes WHO’s continued efforts to tackle one of the greatest health challenges of our lifetimes. We need to capture the political momentum before and during the UN High-Level Meeting in September to bend the...
Read morePublications
See allTrade and Health Agenda: A Meaningful World Trade Organization Roadmap to Strengthen Global Health
Ahead of the 14th WTO Ministerial Conference (MC14), trade associations representing the pharmaceutical industry provide a perspective on how WTO Members can a roadmap to strengthen global health through meaningful trade policies.
Read more
Value of investment on NCDs: Impact on health outcomes in low- and middle-income countries
In new research commissioned by IFPMA, Airfinity has determined that an additional investment of 1% of GDP toward domestic general government health expenditure in low- and middle-income countries (LMICs) would amount to a US$ 310 billion additional investment, representing a 33% increase in current spending. This research is a response to the UHC 2030 action agenda...
Read more
From innovation to access: Pharmaceutical industry priorities ahead of the 4th UN High-Level Meeting on NCDs and Mental Health
Non-communicable diseases (NCDs), such as diabetes, cardiovascular, renal and metabolic diseases, cancer, chronic respiratory diseases, mental health and neurological diseases, are one of the greatest global health and economic threats we face in our lifetime. Since 2000, global deaths due to NCDs have increased rapidly, even as deaths due to communicable diseases have declined. The...
Read more
Expert insights
See all
The power of vaccines to reduce the impact of chronic diseases
Read more
Strong regulatory systems support the pharmaceutical industry in delivering better health outcomes
Read more
Adaptive HTA: striking the right balance between rapid assessments and local health impact
Read moreResources
See allOur Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
Action on NCDs: How the innovative pharmaceutical industry helps bridge the care gap
Read more